Health Canada gives Paladin priority review
February 4, 2010 by leonardzehr · Leave a Comment
Paladin Labs’ (TSX:PLB) new drug submission for sublingual fentanyl has been accepted for priority review by Health Canada, which provides for a 180-day review cycle. “Abstral is an innovative product that will fulfill an unmet need for cancer patients in Canada and will complement our growing promoted pain portfolio, which includes Tridural, Metadol and Pennsaid,” [...]
Listen to BioTuesdays 
